Jason Andrade Presents Evidence Supporting Reduced Need for OAC Post-AF Ablation
Jason Andrade, Cardiologist at Vancouver Coastal Health, Elite Expert in Atrial Fibrillation, Co-chair of CCS, posted on X:
”In light of the recently published ALONE-AF trial, which tested the hypothesis that OAC discontinuation post ablation was a safe(r) strategy for patients I thought it would be good to review our recently larger meta-analysis on the topic.
In this analysis we examined 63 RCTs containing 11,161 patients
We found catheter ablation:
– Reduced the risk of stroke by 37% (7 less stroke per 1000 treated patients)
– Reduced the risk of death by 23% (16 less deaths per 1000 treated patients)
In conclusion, this large analysis of multiple RCTs shows that ablation reduces hard cardiovascular outcomes with high certainty.
Thus providing rationale for why OAC may not be necessary post ablation, as the risk of stroke is substantially reduced (eg 1.5% in OPTION, and 0.3-0.8% in ALONE-AF).”
Read the full study here.
Title: Catheter and Surgical Ablation for Atrial Fibrillation: A Systematic Review and Meta-analysis
Authors: Bryce Montané, Shiyang Zhang, Jonathan D. Wolfe, Sabrina Prime, Chongliang Luo, Daniel H. Cooper, Michelle Doering, Carina Blomstrom-Lundqvist, Samer A.M. Nashef, Pavel Osmancik, Jason G. Andrade, Emanuele Bertaglia, Ratika Parkash, Daniel B. Mark, Jens C. Nielsen, Linda D. Sharples, Brian F. Gage
Stay updated with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh Reflects on International Plasma Awareness Week
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation